Congestive heart failure and thrombosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 18: | Line 18: | ||
*Retarding progression of [[Heart failure]]. | *Retarding progression of [[Heart failure]]. | ||
*Increase survival. | *Increase survival. | ||
==Supportive Trial Data== | |||
==See also== | ==See also== | ||
Revision as of 15:06, 30 September 2011
Editors-in-Chief: C. Michael Gibson, M.S., M.D. Associate Editor-In-Chief: Ujjwal Rastogi, MBBS [1]
|
Thrombosis Microchapters |
|
Site of Thrombosis |
|---|
|
Differentiating Thrombosis from other Diseases |
|
Diagnosis |
|
Treatment |
|
Congestive heart failure and thrombosis On the Web |
|
to Hospitals Treating Congestive heart failure and thrombosis |
|
Risk calculators and risk factors for Congestive heart failure and thrombosis |
Overview
Heart failure is one of the most important public health problems, afflicting an approximate half million patients in United States, with more than 400,000 new cases each year, and many more worldwide[1]. CHF results when heart is not able to meet the demands of circulation causing insufficient blood flow. These patients are at higher risk of arterial and venous thrombosis.
Historical Perspective
Throughout history many renowned researchers and health care professionals have contributed to the understanding, definition, and recognition of thrombosis in Heart Failure patients.[2] [3] [4]
Pathophysiology
Stagnation of blood flow, disorder in vascular wall, and blood coagulation system are known factors that participate in the thrombosis formation.
Treatment
Rationale for Antithrombotic therapy in Heart failure
- Prevention of Stroke[5],
- Prevention of Systemic or Pulmonary embolism,
- Prevention of coronary thrombosis,
- Retarding progression of Heart failure.
- Increase survival.
Supportive Trial Data
See also
References
- ↑ Massie BM, Shah NB (1997). "Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management". Am Heart J. 133 (6): 703–12. PMID 9200399.
- ↑ WISHART JH, CHAPMAN CB (1948). "Dicumarol therapy in congestive heart failure". N Engl J Med. 239 (19): 701–4. doi:10.1056/NEJM194811042391902. PMID 18892580.
- ↑ HARVEY WP, FINCH CA (1950). "Dicumarol prophylaxis of thromboembolic disease in congestive heart failure". N Engl J Med. 242 (6): 208–11. doi:10.1056/NEJM195002092420603. PMID 15403339.
- ↑ GRIFFITH GC, STRAGNELL R, LEVINSON DC, MOORE FJ, WARE AG (1952). "A study of the beneficial effects of anticoagulant therapy in congestive heart failure". Ann Intern Med. 37 (5): 867–87. PMID 12986600.
- ↑ Kannel WB, Wolf PA, Verter J (1983). "Manifestations of coronary disease predisposing to stroke. The Framingham study". JAMA. 250 (21): 2942–6. PMID 6227757.